Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market – Market Landscapeby Roots Analysis Roots Analysis provides market research and consul
Given the multifaceted advantages of non-invasive cancer diagnostics, the field has witnessed an increase in the number of players involved in the development of such therapies. In fact, over 125 developers that are presently engaged in the development of liquid biopsies. The market is characterized by the presence of very large (more than 5,000 employees), large (501-5,000 employees), mid-sized (51-500 employees), and small-sized companies / start-ups (up to 50 employees). More than 60 companies were established post 2010, highlighting the growing interest of stakeholders in this domain. In addition, twelve companies were established recently; these include (in alphabetical order) Cyclomics (2018), Delee (2017), EarlyDx (2017), Elypta (2017), Geneseq Biosciences (2017), Mursla (2017), Nanostics (2017), Naveris (2017), SanoLiBio (2017), Savran Technologies (2018), Sienna Cancer Diagnostics (2017), and Torpedo Diagnostics (2017).
Maximum number of products (72) are available / under development for diagnosis of lung cancer. This is primarily because lung tissue, being inaccessible, requires invasive methods for diagnosis, which can be complex and painful for the patient. It is important to mention that lung cancer has one of the highest mortality rates with approximately 1.8 million deaths reported in 2018.
This is followed by products for the diagnosis of colorectal cancer (59) and breast cancer (40). In addition, the recent years have seen an increasing awareness for early prostate cancer diagnosis as prostate cancer is the second leading cancer that causes death in men, in the US. Examples of products for the diagnosis of prostate cancer include (in alphabetical order) AdnaTest EMT-2/StemCell (QIAGEN), CellMax-Prostate Cancer Test (CellMax Life), and Claros 1 (OPKO Health).
Majority of the liquid biopsies (137) are being developed for diagnosis / early diagnosis of different cancer indications because it is believed that early diagnosis offers a better survival rate of patients and decreases the economic burden associated with treating late-stage cancer patients. Examples of the products available for diagnosis / early diagnosis include (in alphabetical order) CellMax-CRC Colorectal Cancer Early Detection Test (CellMax Life), EarlyTect-GI Syndecan2 Methylation Assay (Genomictree), and Epi proColon (Epigenomics).
Further, Majority of the products (37%) have a turnaround time of less than or equal to one day; examples of such products include (in alphabetical order) ExoDx Lung(T790M) (Exosome Diagnostics), IntPlex (DiaDx), and IvyGene Liver Test (Laboratory for Advanced Medicine).
Created on Jun 24th 2020 07:19. Viewed 67 times.